Neuroprotective Effect of Cannabinoids in Neurodegenerative Diseases

Authors

  • Carlos Suero-García Departamento de Farmacia y Tecnología Farmacéutica. Facultad de Farmacia. Universidad de Sevilla
  • Lucía Martín-Banderas Departamento de Farmacia y Tecnología Farmacéutica. Facultad de Farmacia. Universidad de Sevilla
  • M. Ángeles Holgado Departamento de Farmacia y Tecnología Farmacéutica. Facultad de Farmacia. Universidad de Sevilla

Keywords:

Cannabis Sativa, cannabinoids, neuroprotection, neurodegeneration, cancer

Abstract

Objectives. It is analysed the actual situation of the investigations related to cannabinoids substances,as well as their interaction with the organism, classification, therapeutics effects and their use in neurodegenerativediseases.

Methods. This study is based on the review of multiples scientific articles directly related with the cannabinoidessubstance and its synthetic derivates, with a special attention on the way the organism interactsand the effects the substances cause in it. Specifically, the study will get deep into the neuroantiinflammatoryand analgesic effects of these substances, related with the neuroprotector effect in neurodegenerativediseases such as Alzheimer, Parkinson, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

Results. From thousands years, the Cannabis Sativa has been used by multiples cultures with differentpurposes such as joy, textile, analgesics etc. But is not till ends of the XX century when there are diversescientific studies related with the Cannabis encouraged. The plant has 400 components, 60 of them belongto the cannabinoides group. The main ones are cannabinol, cannabidiol and tetrahidrocannabinol.With the discoverment of the cannabinoids substances, its derivates, and the receptors which interact with them, it is increased the therapeutic possibilities and remarking the neuroprotective effect which these substances contain.

Conclusions. It has been demostraded the huge potential of the cannabinoids as therapeutic substances apart from its analgesic and antiemetic uses, that is, neurodegenaritve diseases in which they can not only decrease its symptons but stop disease process. Another possible application could be in the oncologic area, being particularly intense the investigation´s activity realised the last 15 years.

Downloads

Download data is not yet available.

References

Bruneton J, Villar del Fresno AM, Carretero Accame E, Rebuelta Lizabe M. Farmacognosia: fitoquímica, plantas medicinales. 2ª ed. Zaragoza: Editorial Acribia; 2001. 1099 p.

Bravo Díaz L. Farmacognosia. Madrid: Editorial Elsevier; 2003. 356 p.

Abood ME, Sorensen RG, Stella N. endoCANNABINOIDS. New York: Editorial Springer; 2013. 286 p.

Niesink RJ, van Laar MW. Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Front. Psychiatry. 2013; 16 (4): 130 (doi: 10.3389/fpsyt.2013.00130)

Muñoz-Rubio I, Cózar-Bernal M.J, Álvarez-Fuentes J, Martín-Banderas L, Fernández-Arévalo M, Holgado M.A. Aplicaciones de los cannabinoides como agentes terapéuticos. Ind. Farm. 2011; 163: 68-77

Köfalvi A. Cannabinoids and the Brain. New York: Editorial Springer; 2008. 583 p.

Stella N. Chronic THC intake modifies fundamental cerebellar functions. J. Clin. Invest. 2013; 123 (8): 3208-3210.

Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev. Bras. Psiquiatr. 2008; 30 (3): 271-280.

Reggio PH. The Cannabinoid Receptors. Greensboro: Editorial Springer; 2009. 402 p.

Hernán Perez de la Ossa, D, Lorente M, Gil-Alegre ME, Torres S, Garcia-Taboada E, Aberturas M.R. Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. PLoS One 2013; 8 (1): e54795.

Molina PE, Amedee A, LeCapitaine NJ, Zabaleta J, Mohan M, Winsauer P, Cannabinoid neuroimmune modulation of SIV disease. J. Neuroimmune Pharmacol. 2011; 6 (4): 516-527.

Krowicki ZK. Involvement of hindbrain and peripheral prostanoids in gastric motor and cardiovascular responses to delta-9-tetrahydrocannabinol in the rat. J. Physiol. Pharmacol. 2012; 63 (6): 581-588.

Saito VM, Rezende RM, Teixeira AL. Cannabinoid modulation of neuroinflammatory disorders. Curr. Neuropharmacol. 2012; 10 (2): 159-166.

Campbell VA, Gowran A. Alzheimer’s disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 2007; 152 (5): 655-662.

Martin-Moreno AM, Brera B, Spuch C, Carro E, Garcia-Garcia L, Delgado M, Pozo MA, Innamorato NG, Cuadrado A, de Ceballos ML. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012; 9 (8): 1-15

Valdeolivas S, Satta V, Pertwee RG, Fernandez-Ruiz J, Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chem. Neurosci. 2012; 3 (5): 400-406.

Garcia C, Palomo-Garo C, Garcia-Arencibia M, Ramos J, Pertwee R, Fernandez-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Delta(9)-THCV in animal models of Parkinson’s disease. Br. J. Pharmacol. 2011; 163 (7): 1495-1506.

Oreja-Guevara C. Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids. Rev. Neurol. 2012; 55 (7): 421-430.

Syed YY, McKeage K, Scott LJ. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Drugs 2014; 74 (5): 563-578.

Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol. 2013; 12 (9): 857-865.

Carter GT, Abood ME, Aggarwal SK, Weiss MD. Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials. Am. J. Hosp. Palliat. Care 2010; 27 (5): 347-356.

Downloads

Published

2015-06-20

How to Cite

1.
Suero-García C, Martín-Banderas L, Holgado M Ángeles. Neuroprotective Effect of Cannabinoids in Neurodegenerative Diseases. Ars Pharm [Internet]. 2015 Jun. 20 [cited 2024 Jul. 21];56(2):77-8. Available from: https://revistaseug.ugr.es/index.php/ars/article/view/4124

Issue

Vol. 56 No. 2 (2015)

Section

Review Articles

License

The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:

  1. The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.

b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.

c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).